Physician profile
Jorge Ayub
NPI 1902876162
$23,183.04
in general payments reported to CMS, 2019-2025
73 companies · $2,580 in 2025
The $2,580 reported for 2025 was more than what a typical Medical Oncology provider received nationally (typical 2025 total: $1,158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,320 · 2020: $6,369 · 2021: $2,785 · 2022: $3,774 · 2023: $2,380 · 2024: $1,975 · 2025: $2,580.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,831 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $78.95 · Education: $25.42.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,830.56 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $78.95 |
| Education | $25.42 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $4,870.39 | 2020-2025 | Calquence, Imfinzi, Enhertu |
| Janssen Biotech, INC. | $2,967.01 | 2019-2025 | Darzalex, Tecvayli, Imbruvica |
| Seagen INC. | $1,814.46 | 2019-2023 | Tukysa, Padcev |
| Celgene Corporation | $1,708.11 | 2019-2025 | Reblozyl, Opdualag |
| Eisai INC. | $1,328.36 | 2020-2024 | |
| E.R. Squibb & Sons, L.L.C. | $965.47 | 2019-2025 | Opdivo, Opdualag, Krazati |
| Novartis Pharmaceuticals Corporation | $815.41 | 2019-2025 | |
| Pfizer INC. | $659.63 | 2019-2025 | |
| Daiichi Sankyo INC. | $637.33 | 2020-2025 | Enhertu, Datroway |
| Adaptive Biotechnologies Corporation | $600.00 | 2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $497.09 | 2019-2025 | |
| Genentech USA, INC. | $488.68 | 2019-2024 | Polivy, Phesgo, Columvi |
| Merck Sharp & Dohme LLC | $452.78 | 2019-2025 | Keytruda, Lynparza, Welireg |
| Glaxosmithkline, LLC. | $381.30 | 2020-2025 | Ojjaara, Blenrep, Jemperli |
| Genzyme Corporation | $310.52 | 2021-2025 |
Show all 73 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jorge Ayub listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.